Asundexian does not reduce the risk of recurrent strokes after non-cardioembolic ischemic stroke
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...
1. The composite of MRI-detected brain infarcts and symptomatic ischemic stroke was comparable across different doses of asundexian and placebo. ...
1. In patients with atrial fibrillation over 65, treatment with rivaroxaban compared to apixaban was associated with a significantly increased ...
1. Therapeutic anticoagulation with rivaroxaban or enoxaparin did not improve clinical outcomes and increased bleeding compared with prophylactic anticoagulation. 2. ...
1. In this randomized controlled trial, rivaroxaban and warfarin were similar in safety and efficacy when used to prevent early ...
Image: PD 1. Rivaroxaban is non-inferior to standard therapy of enoxaparin and vitamin K antagonist in treating acute, symptomatic deep-vein ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.